Cardiac electrical abnormalities in childhood acute lymphoblastic leukemia survivors: a systematic review

[1] Steliarova-Foucher E(2017)International incidence of childhood cancer, 2001–10: a population-based registry study Lancet Oncol 18 719-731

[2] Colombet M(2001)Long-term survival of children with leukemia achieved by the end of the second millennium Cancer 92 1977-1983

[3] Ries LAG(1991)Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood N Engl J Med 324 808-815

[4] Moreno F(2018)Burden of cardiovascular risk factors and cardiovascular disease in childhood cancer survivors: data from the German CVSS-study Eur Heart J 39 1555-1562

[5] Dolya A(2013)Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association Circulation 128 1927-1995

[6] Bray F(2016)Cardiac outcomes in survivors of pediatric and adult cancers Can J Cardiol 32 871-880

[7] Brenner H(1991)Cardiac toxicity 4 to 20 years after completing anthracycline therapy JAMA 266 1672-1677

[8] Kaatsch P(1997)Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience J Clin Oncol 15 1544-1552

[9] Burkhardt-Hammer T(2003)Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study Cancer 97 1991-1998

[10] Harms DO(2005)Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia J Clin Oncol 23 2629-2636

[1] Steliarova-Foucher E(2017)International incidence of childhood cancer, 2001–10: a population-based registry study Lancet Oncol 18 719-731

[2] Colombet M(2001)Long-term survival of children with leukemia achieved by the end of the second millennium Cancer 92 1977-1983

[3] Ries LAG(1991)Late cardiac effects of doxorubicin therapy for acute lymphoblastic leukemia in childhood N Engl J Med 324 808-815

[4] Moreno F(2018)Burden of cardiovascular risk factors and cardiovascular disease in childhood cancer survivors: data from the German CVSS-study Eur Heart J 39 1555-1562

[5] Dolya A(2013)Long-term cardiovascular toxicity in children, adolescents, and young adults who receive cancer therapy: pathophysiology, course, monitoring, management, prevention, and research directions: a scientific statement from the American Heart Association Circulation 128 1927-1995

[6] Bray F(2016)Cardiac outcomes in survivors of pediatric and adult cancers Can J Cardiol 32 871-880

[7] Brenner H(1991)Cardiac toxicity 4 to 20 years after completing anthracycline therapy JAMA 266 1672-1677

[8] Kaatsch P(1997)Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience J Clin Oncol 15 1544-1552

[9] Burkhardt-Hammer T(2003)Late anthracycline cardiotoxicity after childhood cancer: a prospective longitudinal study Cancer 97 1991-1998

[10] Harms DO(2005)Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia J Clin Oncol 23 2629-2636